Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 4/20 | 0.55 |
| ▸ | FBP1 | P09467 | 2/20 | 0.55 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.55 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.55 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.55 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469888 | 1.00 | P2RY2 (0.55) | P2RY2FBP1DNPH1PRKAB2TRPM2 | |
| SCHEMBL17789098 | 1.00 | P2RY2 (0.55) | P2RY2FBP1DNPH1PRKAB2TRPM2 | |
| SCHEMBL16489876 | 1.00 | P2RY2 (0.55) | P2RY2FBP1DNPH1PRKAB2TRPM2 | |
| SCHEMBL17809091 | 1.00 | P2RY2 (0.55) | P2RY2FBP1DNPH1PRKAB2TRPM2 | |
| SCHEMBL14946156 | 1.00 | P2RY2 (0.55) | P2RY2FBP1DNPH1PRKAB2TRPM2 | |
| SCHEMBL5501347 | 1.00 | P2RY2 (0.55) | P2RY2FBP1DNPH1PRKAB2TRPM2 | |
| SCHEMBL625445 | 0.90 | P2RY2 (0.62) | P2RY2P2RY1P2RY11P2RY6P2RY4 | |
| SCHEMBL3503039 | 0.90 | P2RY2 (0.62) | P2RY2P2RY1P2RY11P2RY6P2RY4 | |
| SCHEMBL21742739 | 0.90 | P2RY6 (0.66) | P2RY6P2RY14NT5E | |
| SCHEMBL11511464 | 0.88 | P2RY2 (0.56) | P2RY2FBP1DNPH1PRKAB2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4108671-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3590949-B1 | RIBONUCLEIC ACIDS CONTAINING N1-METHYL-PSEUDOURACILS AND USES THEREOF | MODERNATX INC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3590949-A1 | RIBONUCLEIC ACIDS CONTAINING N1-METHYL-PSEUDOURACILS AND USES THEREOF | ModernaTX, Inc. (US) | 2020-01-08 | — | — | EP | disclosed |
| US-20190160185-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
| EP-2622064-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20170239374-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-24 | — | — | US | disclosed |
| US-20170239374-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-24 | — | — | US | disclosed |
| US-9657295-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNATX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657295-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNATX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160264975-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-09-15 | — | — | US | disclosed |
| US-20160022774-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20140371302-A1 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES | MODERNATX, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371302-A1 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES | MODERNATX, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014158795-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MODERNA THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20130203115-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203115-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2013101690-A1 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES | modeRNA Therapeutics (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20130102034-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2013-04-25 | — | — | US | disclosed |
| US-20130102034-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2013-04-25 | — | — | US | disclosed |
| WO-2012045075-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | SCHRUM JASON (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022774-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MMP1, COL2A1, COL1A1 | P2RY2 2517/4885FBP1 3425/4885DNPH1 4562/4885 |
| US-20170239374-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, RNMT | P2RY2 622/4885FBP1 1693/4885DNPH1 402/4885 |
| US-20190160185-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, RNMT | P2RY2 622/4885FBP1 1693/4885DNPH1 402/4885 |
| US-20130102034-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, RNMT | P2RY2 622/4885FBP1 1693/4885DNPH1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.